Navigation Links
Sentrx Exits 2008 with Strong Growth

Sentrx, a New Jersey drug safety specialty firm, announced today that the company grew the number of pharmacovigilance outsourcing contracts by more than 50% in 2008. Revenues for the year increased 25% over 2007. The domestic service provider added long-term contracts in clinical trial and post-marketing safety, managed safety system hosting, and risk evaluation and mitigation strategies. The company maintained its strong record of regulatory compliance during this period of growth.

Little Falls, NJ (PRWEB) January 20, 2009 - Sentrx, the leading provider of drug safety services, announced today that the company grew the number of pharmacovigilance outsourcing contracts by more than 50% in 2008. Revenues for the year increased 25% over 2007.

Sentrx pioneered the concept of drug safety outsourcing and safety system hosting for clinical trials and post-marketed products in 1999. Since that time, Sentrx has provided operational and consulting services to nearly eighty unique clients. More than fifty of those companies have outsourced adverse event processing, safety system management, or risk evaluation and mitigation strategies (REMS) to Sentrx.

Sentrx provides services from its headquarters in Little Falls, NJ. In addition to a staff of office-based health care professionals, the company utilizes its network of highly experienced drug safety investigators across the United States. This flexible workforce allows Sentrx to handle volume fluctuations and extended coverage hours for its clients, which benefit from the quality, reliability and convenience of a domestic service provider.

Highlights of new business in 2008 include:

¨ Managed safety system hosting for seven biopharmaceutical companies and a large generic manufacturer
¨ Post-marketing safety surveillance for two specialty pharmaceutical companies
¨ Clinical trial safety monitoring for four biopharmaceutical companies
¨ REMS with Elements to Assure Safe Use for a biopharmaceutical company
¨ Safety system consulting engagements at three large companies
¨ Data migration projects at two specialty pharmaceutical companies
¨ Risk management plans authored and approved for two New Drug Applications
¨ Contract renewal and expansion with several existing clients

Other accomplishments in 2008 include:

¨ Installation of Phase Forward's Empirica™ Trace 4.2 in the Sentrx Hosting Center
¨ Implementation of the first hosted client on Empirica Trace
¨ Positive results from seventeen qualification inspections and client audits
¨ Participation in eleven regulatory health authority inspections conducted at client sites with no major findings

"Growing revenue 25 % is a great accomplishment for Sentrx," said Joseph Albano, Chief Executive Officer of Sentrx, "but I am most proud of our consistent record of compliance. As our client base grows, so does the level of scrutiny our people, processes and technology undergo. The regulatory audit results combined with our financial results demonstrate that Sentrx is the drug safety services provider that companies can rely on."

About Sentrx
Sentrx is a leading provider of technology-enabled solutions and services for global drug safety. Its mission is to help pharmaceutical, biotechnology, medical device, and consumer health companies document the safety profile of their products during clinical development and post-approval, enabling them to minimize risks and maximize benefits. Through its multilingual Safety Response Center in Little Falls, NJ, Sentrx delivers a unique combination of highly skilled people, exclusive technology, and best practices in drug safety monitoring. To learn more about Sentrx, please call 1-888-399-8032, extension 261; visit the Sentrx website at; or
view the Sentrx movie at


Read the full story at

Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Related biology technology :

1. Matching Genetics, Technology and Management Practices Critical to Meeting Strong Demand for Agricultural Crops
2. China Biologic Products Reports Strong Third Quarter 2008 Results
3. ACORN CRO Continues Growth in Strong Third Quarter
4. Varian, Inc. Reports Strong Fourth Quarter 2008 Results
5. OmniComm Systems, Inc. Is Fueled by Another Strong Quarter Delivering Electronic Data Capture (EDC) Solutions & Services
6. Shires New Product Portfolio Delivers Strong Quarterly Performance
7. Cephalon Reports Another Strong Quarter
8. Innovation and Strong Therapeutic Potential Seen in Adult Stem Cells, According to Frost & Sullivan
9. Strong elasticity size effects in ZnO nanowires
10. Senetek Affirms Strong Financial Position
11. Dry adhesive based on carbon nanotubes gets stronger, with directional gripping ability
Post Your Comments:
(Date:6/23/2016)... 2016   Boston Biomedical , an industry ... to target cancer stemness pathways, announced that its ... Drug Designation from the U.S. Food and Drug ... including gastroesophageal junction (GEJ) cancer. Napabucasin is an ... cancer stemness pathways by targeting STAT3, and is ...
(Date:6/23/2016)... , June 23, 2016 Houston Methodist ... the Cy-Fair Sports Association to serve as their ... agreement, Houston Methodist Willowbrook will provide sponsorship support, ... connectivity with association coaches, volunteers, athletes and families. ... the Cy-Fair Sports Association and to bring Houston ...
(Date:6/23/2016)... 2016  The Biodesign Challenge (BDC), a university competition ... harness living systems and biotechnology, announced its winning teams ... New York City . The ... projects at MoMA,s Celeste Bartos Theater during the daylong ... senior curator of architecture and design, and Suzanne ...
(Date:6/23/2016)... ... June 23, 2016 , ... STACS DNA Inc., the sample tracking software ... State Crime Laboratory, has joined STACS DNA as a Field Application Specialist. , ... Tremblay, President and COO of STACS DNA. “In further expanding our capacity as a ...
Breaking Biology Technology:
(Date:5/9/2016)... UAE, May 9, 2016 Elevay ... comes to expanding freedom for high net worth professionals ... in today,s globally connected world, there is still no ... could ever duplicate sealing your deal with a firm ... passports by taking advantage of citizenship via investment programs ...
(Date:4/28/2016)... , April 28, 2016 First quarter ... (139.9), up 966% compared with the first quarter of 2015 ... totaled SEK 589.1 M (loss: 18.8) and the operating margin was ... (loss: 0.32) Cash flow from operations was SEK 249.9 ... 2016 revenue guidance is unchanged, SEK 7,000-8,500 M. The ...
(Date:4/19/2016)... 20, 2016 The new GEZE ... compact web-based "all-in-one" system solution for all door components. ... or the door interface with integration authorization management system, ... systems. The minimal dimensions of the access control and ... building installations offer considerable freedom of design with regard ...
Breaking Biology News(10 mins):